Ramipril Capsule
Product Images NDC 51655-406

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Ramipril (NDC 51655-406). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (51655 406 52)

Label for Ramipril Capsules, USP 10 mg. The label indicates a package of 30 capsules, prescription only, with storage instructions at controlled room temperature (20°-25°C). It includes dosage advisory to see the package insert and safety notes for storage and child safety. The labeler is Northwind Health Company, LLC, and the NDC is 51655-406-52.*

FDA Label Image

Figure 1. Kaplan-meier Estimates Of The Composite Outcome Of Myocardial Infarction, Stroke, Or Death From Cardiovascular Causes In The Ramipril Group And The Placebo Group (Ramipril Fig1)

A line graph showing the proportion of patients over days of follow-up comparing Ramipril and Placebo. The x-axis represents days of follow-up up to about 1600 days, and the y-axis shows the proportion of patients from 0 to 0.20. Two lines depict patient proportions over time: a solid line for Ramipril and a dashed line for Placebo, with the Placebo group having a higher proportion of patients. Statistical significance indicated by P=0.0001.*

FDA Label Image

Figure 2. The Beneficial Effect Of Treatment With Ramipril On The Composite Outcome Of Myocardial Infarction, Stroke, Or Death From Cardiovascular Causes Overall And In Various Subgroups (Ramipril Fig2)

A forest plot showing the relative risk of composite outcomes in patients taking Ramipril versus placebo across various subgroups, including overall population, cardiovascular disease status, diabetes, age, sex, hypertension, coronary artery disease history, prior myocardial infarction, cerebrovascular disease, peripheral vascular disease, and microalbuminuria. The plot includes number of patients, incidence percentages in placebo group, and 95% confidence intervals for each subgroup's relative risk in the Ramipril group.*

FDA Label Image

Chemical Structure (Ramipril Str)

Chemical structure diagram of ramipril, showing its molecular framework with labeled chemical groups as part of the active ingredient in the product Ramipril 10 mg capsule by Northwind Health Company, LLC.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.